Aditxt, Inc. — fact timeline

Aditxt, Inc. issued convertible note to Investors for an aggregate original principal amount equal to approximately the sum of $725,000 in cash proceeds plus the sum of the outstanding obligations under the Existin.

“new series of senior secured convertible notes (the “ Notes ”), as joint and several co-borrowers, with an aggregate original principal amount equal to approximately the sum of $725,000 in cash proceeds plus the sum of the outstanding obligations under the Existing Notes (as defined below), subject to a 35% original issue discount, as provided in the Notes. The”

Aditxt, Inc. entered into Pledge Agreement with Collateral Agent (effective 2026-06-03).

“Additionally, on June 3, 2026, pursuant to and in connection with the Purchase Agreement, the Company entered into a Pledge Agreement (the “ Pledge Agreement ”) by and between the Company and the Collateral Agent, pursuant to which the Company pledged as collateral the equity held by the Company in Ignite.”

Aditxt, Inc. entered into Security and Pledge Agreement with Collateral Agent (effective 2026-06-03).

“Additionally, on June 3, 2026, pursuant to and in connection with the Purchase Agreement, Ignite entered into a Security and Pledge Agreement (the “ Security Agreement ”) with the collateral agent named therein (the “ Collateral Agent ”), pursuant to which the Ignite granted to the Collateral Agent, for the ratable benefit of the Investors, a valid, perfected and enforceable security interest in certain assets of the Ignite and its subsidiaries, which assets include substantially all of the assets of Ignite.”

Aditxt, Inc. entered into Note Purchase Agreement with Ignite Proteomics LLC and the investors named therein valued at aggregate original principal amount equal to approximately the sum of $725,000 in cash proceeds plus (effective 2026-06-03).

“On June 3, 2026, Aditxt, Inc. (the “ Company ”) entered into a Note Purchase Agreement (the “ Purchase Agreement ”) by and among the Company, Ignite Proteomics LLC, a Delaware limited liability company and the Company’s wholly owned subsidiary (“ Ignite ”), and the investors named therein (the “ Investors ”), pursuant to which the Company and Ignite issued and sold to the Investors a new series of senior secured convertible notes (the “ Notes ”), as joint and several co-borrowers, with an aggregate original principal amount equal to approximately the sum of $725,000 in cash proceeds plus the sum of the outstanding obligations under the Existing Notes (as defined below), subject to a 35% original issue discount, as provided in the Notes.”

Brian Brady resigned as non-executive Chairman and board member at Aditxt, Inc..

“On June 2, 2026, Brian Brady resigned as non-executive Chairman of the Board as well as a member of the Board, effective immediately.”

Christopher J. Porcelli resigned as General Counsel, Chief People Officer and Corporate Secretary at Aditxt, Inc..

“On June 2, 2026, Christopher J. Porcelli notified the Company of his decision to resign as General Counsel, Chief People Officer and Corporate Secretary of Aditxt, Inc. (the “Company”) effective immediately.”

Brian Brady was appointed as Chairman of the Board at Aditxt, Inc..

“On May 31, 2026, the Board appointed Brian Brady, an independent director of the Company, to serve as non-executive Chairman of the Board, effective as of such date.”

Jeffrey M. Busch was appointed as Interim Chief Executive Officer at Aditxt, Inc..

“On May 31, 2026, the Board appointed Jeffrey M. Busch, age 68, to serve as Interim Chief Executive Officer of the Company, effective as of such date.”

Shahrokh Shabahang resigned as Director at Aditxt, Inc..

“On May 31, 2026, Shahrokh Shabahang resigned as a member of the Board, effective immediately.”

Rowena Albanna resigned as Chief Operating Officer at Aditxt, Inc..

“On May 31, 2026, Rowena Albanna notified the Company of her decision to resign as Chief Operating Officer of the Company, effective June 5, 2026.”

Amro Albanna resigned as Director at Aditxt, Inc..

“On May 29, 2026, Amro Albanna notified the Company of his decision to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.”

Amro Albanna resigned as Chief Executive Officer at Aditxt, Inc..

“On May 29, 2026, Amro Albanna notified the Company of his decision to resign as Chief Executive Officer of Aditxt, Inc. (the “Company”), and on May 30, 2026, Mr. Albanna resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately.”

Aditxt, Inc. received a nasdaq hearing update notice regarding other (rules 5550(a)(2), 5550(b)(1)).

“May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further”

Aditxt, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 27, 2026, Aditxt, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum stockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”). The Letter further”

Aditxt, Inc.: Authorized and implemented a 1-for-27 reverse stock split via amendment to certificate of incorporation (effective 2026-05-15).

“On May 14, 2026, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split. The Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on May 15, 2026”

Aditxt, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).

“May 6, 2026, Aditxt, Inc. (the “Company”) received a Staff Determination letter (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that”

Aditxt, Inc. incurred senior notes of aggregate original principal amount of $1,250,000 at 10% per annum maturing mature on September 30, 2026.

“On April 10, 2026, Aditxt, Inc. (the “Company”) issued and sold senior unsecured promissory notes (each, a “Note,” and collectively, the “Notes”) to accredited investors in the aggregate original principal amount of $1,250,000 for an aggregate purchase price of $1,000,000, reflecting an aggregate original issue discount of $250,000.”

Aditxt, Inc. entered into Note with accredited investors valued at aggregate original principal amount of $1,250,000 (effective 2026-04-10).

“On April 10, 2026, Aditxt, Inc. (the “Company”) issued and sold senior unsecured promissory notes (each, a “Note,” and collectively, the “Notes”) to accredited investors in the aggregate original principal amount of $1,250,000 for an aggregate purchase price of $1,000,000, reflecting an aggregate original issue discount of $250,000.”

Aditxt, Inc.: Filed Certificate of Designations creating Series A-2 Convertible Preferred Stock (effective 2026-03-10).

“On March 10, 2026, the Company filed the Certificate of Designations with the Delaware Secretary of State designating, 36,000 shares of its authorized and unissued Preferred Shares as Series A-2 Convertible Preferred Shares (the “Preferred Shares”).”

Aditxt, Inc. incurred loan of aggregate principal amount of $3,194,444.44 with several buyers listed on the issuance schedule attached thereto at 6% per annum maturing nine months from the issuance date.

“On March 11, 2026, the Company entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with the several buyers listed on the issuance schedule attached thereto (the “Note Buyers”), pursuant to which the Company will issue its 10% original issue discount promissory notes (the “Notes”) for the aggregate principal amount of $3,194,444.44.”

Aditxt, Inc. entered into Securities Purchase Agreement with IMAC Holdings, Inc. valued at 36,000 shares of Series A-2 Convertible Preferred Stock ($36,000,000 total stated value) for 100% eq (effective 2026-03-11).

“On March 11, 2026, Aditxt, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Agreement ") with IMAC Holdings, Inc. (" IMAC ") and the several investors listed on the Schedule of Buyers attached to the Agreement (collectively, the "Buyers") whereby the Buyers sold 100% of their equity interests in Ignite Proteomics, LLC, a Delaware limited liability company (" Ignite ") and formerly a wholly owned subsidiary of IMAC plus $475,000 in cash, for a total consideration of 36,000 shares of the Company's newly created Series A-2 Convertible Preferred Stock (the " Preferred Shares ").”

Aditxt, Inc. completed an acquisition involving IMAC Holdings, Inc. for 36,000 shares of the Company’s newly created Series A-2 Convertible Preferred Stock (closed 2026-03-11).

“Agreement ”) with IMAC Holdings, Inc. (“ IMAC ”) and the several investors listed on the Schedule of Buyers attached to the Agreement (collectively, the “Buyers”)”

Aditxt, Inc.: Amended certificate of incorporation to effect a one-for-eight reverse stock split (effective 2026-03-06).

“On March 5, 2026, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”) to effect the Reverse Stock Split. The Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on March 6, 2026, and the Company’s common stock will begin trading on a split-adjusted basis when the Nasdaq Stock Market opens on March 9, 2026.”

Aditxt, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“December 1, 2025, Aditxt, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, based upon the stockholders’ equity reported by the Company in its Form 10-Q for the period ended September 30, 2025, the Company was no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a company to maintain a minimum of $2,500,000 in stockholders’ equity, a market value of listed securities of at least $35 million, or net income from continuing operations of $500,000 in the most recently”

Aditxt, Inc.: Amended certificate of incorporation to effect a 1-for-113 reverse stock split (effective 2025-10-31).

“On October 31, 2025, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”) to effect the Reverse Stock Split.”

Aditxt, Inc. incurred senior notes of $212,500 aggregate original principal amount with accredited investors at 10% per annum maturing September 30, 2025.

“On September 12, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior unsecured notes (each, a " Note ") to accredited investors in the aggregate original principal amount of $212,500 for a purchase price of $170,000, reflecting an aggregate original issue discount of $42,500.”

Aditxt, Inc. incurred senior notes of $1,000,000 aggregate original principal amount with accredited investors at 10% per annum maturing September 30, 2025.

“On June 26, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior notes (each, a “ Note ”) to accredited investors in the aggregate original principal amount of $1,000,000 for a purchase price of $800,000, reflecting an aggregate original issue discount of $200,000. The Notes bear interest at a rate of 10% per annum and have a maturity date of September 30, 2025 (the “ Maturity Date ”).”

Aditxt, Inc. incurred loan of $90,000 and $100,000 with Amro Albanna and Shahrokh Shabahang at Prime rate of seven and one-half percent (7.5%) per annum maturing July 20, 2025 or an Event of Default.

“On June 20, 2025, Amro Albanna, the Chief Executive Officer of Aditxt, Inc. (the “ Company ”) and Shahrokh Shabahang, the Chief Innovation Officer of the Company loaned $90,000 and $100,000, respectively, to the Company. The loans were each evidenced by an unsecured promissory note (the “ Note ”), each of which will accrue interest at the Prime rate of seven and one-half percent (7.5%) per annum and is due on the earlier of July 20, 2025 or an Event of Default (as defined in the Note).”

Saundra Pelletier was appointed as director at Aditxt, Inc..

“On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.”

Aditxt, Inc. incurred loan of $233,000 with Amro Albanna at Prime rate of seven and one-half percent (7.5%) per annum maturing November 22, 2025.

“On May 22, 2025, Amro Albanna, the Chief Executive Officer of Aditxt, Inc. (the “ Company ”) loaned $233,000 to the Company. The loan was evidenced by an unsecured promissory note (the “ Note ”). Pursuant to the terms of the Note, it will accrue interest at the Prime rate of seven and one-half percent (7.5%) per annum and is due on the earlier of November 22, 2025 or an Event of Default (as defined in the Note).”

Aditxt, Inc. incurred senior notes of original principal amount of $3,114,285.71 with an accredited investor at 10% per annum maturing May 12, 2025.

“the Company issued and sold a 30% Original Issue Discount Senior Secured Note (the " Note ") to an accredited investor in the original principal amount of $3,114,285.71 for a purchase price of $2,000,000. The Note bears interest at a rate of 10% per annum (the “ Interest Rate ”) and has a maturity date of May 12, 2025 (the “ Maturity Date ”).”

Aditxt, Inc. incurred senior notes of $256,250 aggregate original principal amount at 10% per annum maturing May 15, 2025.

“On April 24, 2025, Aditxt, Inc. (the “ Company ”) issued and sold senior notes (each, a " Note ") to accredited investors in the aggregate original principal amount of $256,250 for a purchase price of $205,000, reflecting an aggregate original issue discount of $51,250. The Notes bear interest at a rate of 10% per annum and have a maturity date of May 15, 2025 (the “ Maturity Date ”).”

Aditxt, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“March 7, 2025, the Company was notified by the Listing Qualifications Staff (the “Staff”) of Nasdaq that it has determined that as of March 6, 2025, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days. As a result, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)A)(iii) and the Staff has determined to delist the Company’s securities from The Nasdaq Capital Market. The Company intends to submit an appeal to Nasdaq on March 14, 2025, which will stay the delisting and suspension of the Company’s securities pending t”

Aditxt, Inc.: Certificate of amendment filed to effect a 1-for-250 reverse stock split of common stock, effective March 14, 2025 at 4:01 p.m. ET (effective 2025-03-14).

“On March 12, 2025, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation (the “ Certificate of Amendment ”) to effect the March Reverse Stock Split. The March Reverse Stock Split will become effective as of 4:01 p.m. Eastern Time on March 14, 2025”

Aditxt, Inc. incurred loan of $824,371.06 with Aldevron, LLC at 1.5% per annum maturing May 16, 2025.

“Pursuant to the Settlement Agreement, the Company will pay $1 million and issue a Promissory Note (the “Note”) in the principal amount of $824,371.06 (the “Principal Amount”). The Principal Amount will not bear interest unless it is not repaid in full by its maturity date on May 16, 2025, in which case interest will accrue at a rate of one and one-half percent (1.5%) per annum.”

Aditxt, Inc.: Certificate of incorporation amended to effect a one-for-forty reverse stock split of common stock (effective 2024-10-01).

“On October 1, 2024, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment to its certificate of incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”

Aditxt, Inc. reported a default on lease obligation of $590,557.31 with LS Biotech Eight, LLC at Default Rate as defined in the Lease.

“On May 10, 2024, Aditxt, Inc. (the “ Company ”) received written notice (the “ Notice ”) from LS Biotech Eight, LLC (the “ Landlord ”) that the Company was in violation of its obligation to (i) pay Base Rent (as defined in the Lease) and Additional Rent (as defined in the Lease) in the amount of $431,182.32 in the aggregate, together with administrative charges and interest, as well as (ii) replenish the Security Deposit (as defined in the Lease) in the amount of $159,375.00, all as required under that certain Lease Agreement dated as of May 4, 2021 by and between the Landlord and the Company (the “ Lease ”). Pursuant to the Notice, the Landlord has demanded that a payment of $590,557.31 plus administrative charges and interest, which shall accrue at the Default Rate (as defined in the Lease) be made no later than May 17, 2024.”

Aditxt, Inc.: On May 2, 2024, the Company filed Certificates of Designation for Series C-1 and Series D-1 Preferred Stock with the Secretary of State of Delaware, establishing the terms of these new preferred stock series (effective 2024-05-02).

“On May 2, 2024, the Company filed a Certificate of Designation for its Series C-1 Preferred Stock with the Secretary of State of Delaware (the “ Series C-1 Certificate of Designations ”).”

Aditxt, Inc. entered into Securities Purchase Agreement with certain accredited investors (effective 2024-05-02).

“On May 2, 2024, Aditxt, Inc. (the " Company ") entered into a Securities Purchase Agreement (the " Purchase Agreement ") with certain accredited investors”

Aditxt, Inc. entered into Common Stock Purchase Agreement with an equity line investor (the 'Investor') valued at $150,000,000 (effective 2024-05-02).

“On May 2, 2024, Aditxt, Inc. (the “ Company ”) entered into a Common Stock Purchase Agreement (the “ Purchase Agreement ”) with an equity line investor (the “ Investor ”), pursuant to which the Investor has agreed to purchase from the Company, at the Company’s direction from time to time, in its sole discretion, from and after the date effective date of the Registration Statement (as defined below) and until the termination of the Purchase Agreement in accordance with the terms thereof, shares of the Company’s common stock having a total maximum aggregate purchase price of $150,000,000”

Aditxt, Inc. terminated Agreement and Plan of Merger with Evofem Biosciences, Inc..

“the Company received notice from Evofem (the “ Termination Notice ”) that Evofem was exercising its right to terminate the Merger Agreement as a result of the Company’s failure to provide the Initial Parent Equity Investment (as defined in the Merger Agreement, as amended)”

Aditxt, Inc. entered into Agreement and Plan of Merger with Evofem Biosciences, Inc..

“the Company entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Adifem, Inc. f/k/a Adicure, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Adifem ”) and Evofem Biosciences, Inc., a Delaware corporation (“ Evofem ”)”

Aditxt, Inc. amended Reinstatement and Fourth Amendment to the Merger Agreement with Evofem Biosciences, Inc. valued at $1,000,000 (effective 2024-05-02).

“On May 2, 2024, the Company, Adifem, Inc. f/k/a Adicure, Inc. and Evofem Biosciences, Inc. (“Evofem”) entered into the Reinstatement and Fourth Amendment to the Merger Agreement (the “ Fourth Amendment ”)”

Aditxt, Inc. terminated Agreement and Plan of Merger with Evofem Biosciences, Inc. (effective 2024-04-26).

“On April 26, 2024, the Company received notice from Evofem that Evofem was exercising its right to terminate the Merger Agreement effective immediately as a result of the Company’s failure to provide the Initial Parent Equity Investment (as defined in the Merger Agreement, as amended).”

Aditxt, Inc. entered into Arrangement Agreement with Appili Therapeutics, Inc. (effective 2024-04-01).

“On April 1, 2024 (the “ Execution Date ”), Aditxt, Inc., a Delaware corporation (the “ Company ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”) with Adivir, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Adivir ” or the “ Buyer ”), and Appili Therapeutics, Inc., a Canadian corporation (“ Appili ”), pursuant to which, Adivir will acquire all of the issued and outstanding Class A common shares of Appili”

Aditxt, Inc. amended credit facility of outstanding balance adjusted to $250,000 with Holders at not disclosed maturing March 31, 2024.

“the Company and the Holders entered into a payoff letter (the “ Payoff Letter ”) and amendments to the January 2024 Secured Notes (“ Amendment No. 4 to January 2024 Secured Notes ”), pursuant to which the maturity date of the January 2024 Secured Notes was extended to March 31, 2024 and the outstanding balance under the Notes, after giving effect to the transactions contemplated by the February Assignment Agreement as applied pursuant to the Payoff Letter, was adjusted to $250,000.”

Aditxt, Inc. incurred senior notes of an aggregate principal amount of $5.0 million in ten-year unsecured notes with Holders of senior indebtedness of Evofem at not disclosed maturing maturity date not explicitly stated, ten-year.

“an aggregate principal amount of $5.0 million in ten-year unsecured notes (the “ Unsecured Notes ”)”

Aditxt, Inc. incurred credit facility of an aggregate principal amount of $8.0 million in secured notes of the Company due on September 30, 2024 with Holders of senior indebtedness of Evofem at not disclosed maturing September 30, 2024.

“an aggregate principal amount of $8.0 million in secured notes of the Company due on September 30, 2024 (the “ September 2024 Secured Notes ”)”

Aditxt, Inc. incurred credit facility of an aggregate principal amount of $5.0 million in secured notes of the Company due on January 2, 2024 with Holders of senior indebtedness of Evofem at not disclosed maturing January 2, 2024.

“the Company, Evofem and the holders (the “Holders”) of certain senior indebtedness of Evofem (the “ Notes ”) entered into an Assignment Agreement dated December 11, 2023 (the “ December Assignment Agreement ”), pursuant to which the Holders assigned the Notes to the Company in consideration for the issuance by the Company of (i) an aggregate principal amount of $5.0 million in secured notes of the Company due on January 2, 2024”

Aditxt, Inc. entered into Engagement Letter with Dawson James Securities, Inc. valued at $1.85 million initial fee, plus transaction fee of 5% of first $20.0 million and 10% of excess above (effective 2024-02-16).

“On February 16, 2024, Aditxt, Inc. (the " Company ") entered into an engagement letter (the " Engagement Letter ") with Dawson James Securities, Inc. (" Dawson "), pursuant to which the Company engaged Dawson to serve as financial advisor with respect to one or more potential business combinations involving the Company for a term of twelve months.”